Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429700 | 0.91 | AURKA (0.63) | AURKAAURKBCHEK1FLT3ADORA3 | |
| SCHEMBL14533906 | 0.83 | AURKA (0.51) | AURKAAURKBCHEK1CCNA2CDK2 | |
| SCHEMBL14533907 | 0.79 | AURKA (0.54) | AURKAAURKBADORA3 | |
| SCHEMBL8241235 | 0.78 | AURKA (0.81) | AURKAAURKBCHEK1CCNA2CDK2 | |
| SCHEMBL14534143 | 0.78 | AURKA (0.59) | AURKAAURKBFLT3ADORA3 | |
| SCHEMBL13954832 | 0.76 | AURKB (0.68) | AURKAAURKBCHEK1CDK2 | |
| SCHEMBL8426673 | 0.74 | AURKA (0.56) | AURKAAURKBADORA3 | |
| SCHEMBL8241241 | 0.73 | AURKA (0.90) | AURKAAURKBCHEK1CCNA2CDK2 | |
| SCHEMBL8427761 | 0.73 | AURKA (0.36) | AURKAAURKBADORA3 | |
| SCHEMBL14534037 | 0.71 | AURKA (0.64) | AURKAAURKBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKA 41/4885AURKB 138/4885CHEK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.